ArticleClinical cancer research : an official journal of the American Association for Cancer Research2025

Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma.

William D Tap et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.